Xbrane Biopharma AB · OMXSTO:XBRANE

Xbrane Biopharma AB — Investor Day (September 2022)

57 slides from Xbrane Biopharma AB's investor day presentation, Sep 22, 2022

  1. Slide 1: Capital Markets Day September 22, 2022

    STO: XBRANE Capital Markets Day September 22, 2022 A World-Leading Biosimilar Developer 1

  2. Slide 2: Important information

    Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in

  3. Slide 3: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  4. Slide 4: Biosimilars are follow-on products to biologics post patent expiry

    Biosimilars are follow-on products to biologics post patent expiry. High barriers of entry enable healthy margins. Pharmaceuticals Small Molecules Biologics Molecular Weight: Molecular Weight: ͠ 180 Dalton ͠ 150,000 Dalton → Produced via chemical synthesis → Produced via recombinant DNA technology →

  5. Slide 5: Biosimilars is the fastest growing segment in the pharma market

    Biosimilars is the fastest growing segment in the pharma market. Xbrane is one out of four pure-play biosimilar developers in Europe. Biologics market outgrowing pharma Biosimilar market expected to reach USD 80 billion in 2026 Total global biologics market size (USD billion) Total global biosimilar

  6. Slide 6: Xbrane has established a validated biosimilar development platform

    Xbrane has established a validated biosimilar development platform to capitalize on as first product is launched in Q1 2023 Establish technology platform Establish development platform Capitalize on platform 2008-2015 2015-2022 2023- → Establishment of high yield / low → Development of portfolio add

  7. Slide 7: Experienced management team and board

    Experienced management team and board Management Board of Directors Martin Åmark Siavash Bashiri Maria Edebrink Xiaoli Hu Nina Ivers Anders Tullgren Eva Nilsagård Karin Wingstrand Mats Thorén CEO COO & Head of Head of Head of Business Head of Human Chairman of the Director of the Director of the Dir

  8. Slide 8: Investment highlights: Xbrane – a world-leading biosimilar developer

    Investment highlights: Xbrane – a world-leading biosimilar developer • Xbrane is a world-leading biosimilar developer with a patented high-yield platform ensuring lowest possible production cost Platform biosimilar developer with lowest • Commercial agreement with three major global pharmaceutical c

  9. Slide 9: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  10. Slide 10: Ximluci is a biosimilar candidate to Lucentis

    Ximluci® is a biosimilar candidate to Lucentis® Lucentis® used in treatment of severe eye diseases Global unmet medical need due to high drug cost 5 million affected eyes Europe & US, 50% treated Affected vision Normal vision Undertreated Lucentis Eylea Avastin 0.6 2.5 2.5 1.1 0.8 13 million affecte

  11. Slide 11: Ximluci is a highly similar biologic to Lucentis

    Ximluci® is a highly similar biologic to Lucentis® Biosimilar attribute to Lucentis® Ximluci® Comment Identical amino-acid sequence Comparative Analytical → Involving +10 Ximluci® batches vs. +20 Highly similar structure Assessment Lucentis® batches Highly similar binding properties → Comprehensive

  12. Slide 12: Ximluci European launch planned for Q1 2023

    Ximluci® European launch planned for Q1 2023 2021 2022 2023 XlucaneTM pivotal phase III trial Regulatory process EU Production launch volume Regulatory process US Jun 2021 Feb 2022 July 2022 Nov 2022 Q1 2023 Interim read-out Top-line data Lucentis® LoE EU EU Approval EU Launch Positive CHMP opinion

  13. Slide 13: STADA & Bausch + Lomb to commercialize Ximluci across an €11.7b market

    STADA & Bausch + Lomb to commercialize Ximluci® across an €11.7b market €6.6 billion retinal anti-VEGF market €5.1 billion retinal anti-VEGF market → USD3.4 billion eye product and pharma specialist → €2.6 billion generic and biosimilar specialist → Existing ophthalmic sales force with strong relati

  14. Slide 14: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  15. Slide 15: STADA is a €3B+ generic and biosimilar specialist

    STADA is a €3B+ generic and biosimilar specialist with presence across Europe +8% +37% Net Sales adjusted: EBITDA adjusted: 12,500+ €3,249 million €776 million employees worldwide form One A growth of 8% in 2021 above the a growth of +37% in 2021 STADA market in Generics/Specialty/Consumer Healthcar

  16. Slide 16: STADA has a full presence in all key European markets

    STADA has a full presence in all key European markets • Presence in more than 30 European countries with deep expertise in local markets dynamics • STADA with strong No 4 position in Gx and No 4 in CHC in Europe – track record of outperforming key competitors • Diversified Generics & Specialty portf

  17. Slide 17: STADA has the commercial capabilities, resources and infrastructure

    STADA has the commercial capabilities, resources and infrastructure STADA Sx Capabilities by Market = Leading / at- Full fledged Hospitals/ Whole- Medical scale at-scale Pharmacies = No presence SG&A entity Tender salers doctors • With current footprint, STADA Independent Chains already ensures full

  18. Slide 18: Ximluci addresses a €4 billion market in Europe

    Ximluci® addresses a €4 billion market in Europe. STADA stronghold Germany alone is a €700 million market Europe retinal VEGF inhibitor market € million Main VEGF inhibitors for retinal disorders on the market 5000 CAGR Off-label 4000 8% p.a. Annual sales €1.3b €2.6b <€0.2b n/a Others Europe (€b) 30

  19. Slide 19: Biosimilars uptake rate in Europe is accelerating

    Biosimilars uptake rate in Europe is accelerating Biosimilars have taken +60% of reference product volume Schemes to drive biosimilar adoption in the EU • Multiple new schemes to drive biosimilar adoption introduced across 5EU • Tenders • Prescription targets and quotas for physicians • Financial in

  20. Slide 20: Specialty products – rapidly building capabilities

    STADA with track record of successful commercialization of Biosimilar / Specialty products –rapidly building capabilities around new opportunities 1st pan-European launch achieving 88% biosimilar market share in launch year 20201 1st successful biosimilar Market share still growing commercialisation

  21. Slide 21: STADA has a strong competitive position ahead of Ximluci launch

    STADA has a strong competitive position ahead of Ximluci® launch Key success factors for biosimilar STADA position and capabilities launch • High quality product • Extensive CAA* and Ph3 trial • Timely launch in relation to • Launch planned for Q1 2023 competitors • Low production cost • Xbrane pate

  22. Slide 22: Ximluci launch plan and preparation in core markets

    Ximluci® launch plan and preparation in core markets 2022 2023 • Build-up of dedicated KAMs to target key KOLs / • Phased launch based on local opportunities; compounders continued scale up of field force • Prepare educational material to healthcare • Key customer detail initiation professionals and

  23. Slide 23: Experienced team to lead the launch of Ximluci

    Experienced team to lead the launch of Ximluci® Erin Federman, Surangana Sureka, Dr. Piero Sciotto Bryan Kim, VP, Global Commercial, Director, Global BU Head Biosimilars, Matthieu Lamant, France Nick Ettery, VP Rx EVP, Specialty Care Specialty Care Commercial, Ximluci Germany Director Commercial & B

  24. Slide 24: STADA is actively pursuing opportunities beyond Europe

    STADA is actively pursuing opportunities beyond Europe Bausch & Lomb STADA launch 2023 STADA Under Exploration for next wave Further opportunities 24

  25. Slide 25: QnA on Ximluci

    QnA on Ximluci QnA on Ximluci 25

  26. Slide 26: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  27. Slide 27: Xbrane is a purpose driven organization

    Xbrane is a purpose driven organization Xbrane’s purpose is to enable health equality and bring people back to healthy lives through developing affordable biologics “…the highest attainable standard of health is a fundamental right of every human being.” (WHO, 1946) 27

  28. Slide 28: R&D engine with capacity to initiate one new development program annually

    R&D engine with capacity to initiate one new development program annually Platform with LEMOTM as core technology Diverse, qualified and motivated team State of the art facility Relative yield (g/L) (%) Xbrane team LEMO Standard 100 100% 80 80% 60 60% 40% 40 20% 20 + + 0% 0 Membrane Average of Antib

  29. Slide 29: Validating, world-leading partnerships with >€150m in payable fees

    Validating, world-leading partnerships with >€150m in payable fees Product Ximluci® BIIB801TM Commercial Partner Territory Global ex. China North America Global Type Co-development License License Upfront €7.5m USD5m USD8m >$150m Milestones / Cost coverage €40-50m Undisclosed USD80m Royalties/ profi

  30. Slide 30: Xbrane development portfolio addresses a market of €53 billion

    Xbrane development portfolio addresses a market of €53 billion Originator peak sales estimate 2026* (€ billion) Biosimilar Ximluci™ BIIB801 Xdivane™ Xtrudane™ Xdarzane™ candidate Branded biologics Therapeutic Ophthalmology Immunology Oncology Oncology Oncology area 2020 (US) 2024 (US) 2028 (US) 2029

  31. Slide 31: Xbrane is one out of four EU/US validated pure-play biosimilar developers

    Xbrane is one out of four EU/US validated pure-play biosimilar developers EU/US biosimilar sales and marketing EU/US biosimilar developers without sales companies with limited internal biosimilar and marketing capability development Supply of full portfolio Fill gaps in portfolio Fully integrated bi

  32. Slide 32: Xbrane differentiated focus on high yield vs. EU/US public peers

    Xbrane differentiated focus on high yield vs. EU/US public peers Adressable market with 53 52 20 portfolio (€b): # products under development: 5 8 4 Ranvisio (ranibizumab) Most advanced program: To be launched in EU Q1 To be launched in EU Launched EU June 2022 2023 Manufacturing site No Yes No • 10

  33. Slide 33: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  34. Slide 34: Xbrane's platform technology is a toolbox of proprietary technologies

    Xbranes platform technology is a “toolbox” of proprietary technologies and know-how that results in high yield / low cost production of biosimilars Gene construct Host cell Process Target Protein/Biosimilar PLASMID • Expression control • Proprietary engineered strain library in • USP - Optimal cell

  35. Slide 35: Xbrane's proprietary LEMO promoter enables high-yield & low unit cost

    Xbrane’s proprietary LEMO™ promoter enables high-yield & low unit cost LEMO™ – patented platform regulates production intensity …leading to higher yield and lower cost TARGET Relative yield (g/L) (%) LEMO Standard LIVING PROTEIN CELL O2 100% LEMO™ Glucose Rhamnose 80% PLASMID 60% 12x 5x 3x 40% 20% 0

  36. Slide 36: Case example: 4-5x yield advantage for Cimzia biosimilar

    Case example: 4-5x yield advantage for Cimzia biosimilar Example of Key technologies from “toolbox” used 4-5x yield advantage Gene construct • Rhamex • Signal sequences Relative yield (g/L) (%) • Translation Initiation Region Xbrane (Xcimzane*) Biosimilar Originator (Cimzia*) 100% Host cell 80% • St

  37. Slide 37: Xbrane is expanding its platform to mammalian cells

    Xbrane is expanding its platform to mammalian cells to develop more targets Yield (g/l) 2023 Proprietary 3rd target mammalian strain 2022: Xbrane proprietary expression vector Proprietary CHO strain TIS Construct design 2nd target Signal sequences Vector integration In-house scale-up of + 2021: Sign

  38. Slide 38: Xbrane has successfully expanded its technology platform into mammalian cells

    Xbrane has successfully expanded its technology platform into mammalian cells in the development of Xdivane and other MAB targets Xbrane proprietary technology developed for protein Significant increase in yield for new MAB targets expression in mammalian cells (CHO) • Key proprietary vector technol

  39. Slide 39: QnA on Xbrane technology platform

    QnA on Xbrane technology platform QnA on Xbrane technology platform 39

  40. Slide 40: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  41. Slide 41: Cimzia is a differentiated €1.8 billion TNFa inhibitor

    Cimzia® is a differentiated €1.8 billion TNFa inhibitor Cimzia® is a differentiated TNFa inhibitor Cimzia® generated €1.8 billion in sales 2021 Rheumatoid Arthritis Psoriasis Cimzia® sales (€ millions) 2000 1500 1000 → Cimzia® is a TNFa inhibitor that reduce immune response in auto-immune diseases 5

  42. Slide 42: BIIB801 – the only publicly known Cimzia biosimilar under development

    BIIB801 – the only publicly known Cimzia® biosimilar under development BIIB801 program Partnership with Biogen with attractive terms → Pilot scale process established → Out-licensing of global rights → Ongoing tech-transfer/scale-up to selected drug → Xbrane responsible for and fund pre-clinical sub

  43. Slide 43: BIIB801 will reach break-even for Xbrane by first milestone

    BIIB801 will reach break-even for Xbrane by first milestone Today ILLUSTRATIVE MAA/ Sales and Pre-clinical development Clinical development BLA marketing Agreement CAA pilot Agreement AGC scale Biogen Responsibility under agreement: Milestones $80m Upfront $8m Proceeds Royalties on sales Investments

  44. Slide 44: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  45. Slide 45: Building an oncology biosimilar portfolio

    Building an oncology biosimilar portfolio Opportunity to make a difference €48 billion of addressable annual reference product sales Combined annual expected peak reference product sales € billion 50 45 Darzalex 40 35 30 → Annual per patient cost of SEK 0.5-1 million - significant 25 Keytruda issues

  46. Slide 46: Xbrane is in a strong position to out-license oncology portfolio during 2023

    Xbrane is in a strong position to out-license oncology portfolio during 2023 1• Attractive portfolio 2• Timeline for approval by patent expiry of originator 3• High yield / low cost 4• One of four EU/US pure-play developers with track record 46

  47. Slide 47: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  48. Slide 48: Xbrane long term strategy

    Xbrane long term strategy Vision: Become a leading science based biosimilar developer of cost- effective medicines targeting high unmet medical need utilizing state-of-the art technology Playfield: Competitive advantage: Pure-play biosimilar developer Low production cost via patented Out-license at

  49. Slide 49: Key take-aways

    Key take-aways • One out of four pure-play biosimilar developers in Europe • Addressing fastest growing pharma market segment • Purpose driven organization • Differentiated high yield / low cost production platform • Validated by strong partnerships • Portfolio addressing €53 billion market • First

  50. Slide 50: QnA General questions

    QnA General questions QnA General questions 50

  51. Slide 51: Today's agenda

    Today’s agenda Topic Presenter Introduction Anders Tullgren, Chairman Introduction to Ximluci® Martin Åmark, CEO STADA launch readiness of Ximluci® Bryan Kim, Head of Speciality products STADA QnA on Ximluci® Xbrane – a platform biosimilar developer Martin Åmark, CEO Xbrane platform technology, faci

  52. Slide 52: STO: XBRANE

    JYURRANE STO: XBRANE

  53. Slide 53: Latest financials & shareholder list

    Latest financials & shareholder list Shareholder list (30 June 2022) Financial highlights Investor Name Shares Ownership, % SEK thousands Jan-Jun 2022 Jan-Jun 2021 Serendipity Group 3,177,367 12.7 Swedbank Robur Fonder 2,196,435 8.7 Revenue 22,821 5,090 Bengt Göran Westman 2,055,337 8.2 STADA Arznei

  54. Slide 54: Biosimilars – fast & cost effective path to market with reduced risk

    Biosimilars – fast & cost effective path to market with significantly reduced risk Discovery & Development Pre-clinical Phase I Phase II Phase III Novel Likelihood of Approval1 10% 50% biological drug Development time Capital requirement Prob. of success Premium pricing ~10-12 years > €1 billion LOW

  55. Slide 55: Biosimilars claim majority of originator product's market in few years

    Biosimilars claim majority of originator product’s market in just few years EU biosimilar market share by volume US biosimilar market share by volume 55 Source: IQVIA, Bernstein

  56. Slide 56: Biosimilars – accessible, life critical biologics realizing cost savings

    Biosimilars – accessible, life critical biologics realizing significant cost savings Biosimilars significantly increase access… …and realize significant savings Treatment days per capita Europe US Biosimilar savings USD billion 0.9 120 100% 0.8 104 100 0.7 15% 0.6 80 0.5 60 0.4 0.3 40 0.2 18 19 20%

  57. Slide 57: Milestones coming months

    Milestones coming 18 months • Nov 2022 : Marketing authorisation from the EMA for Ximluci® • Q4 2022 : XlucaneTM FDA-BLA re-submission • Q1 2023 : Ximluci® launch in Europe • H2 2023 : BIIB801 scale-up and program break-even • 2023 : Out-licensing of oncology portfolio • 2023 : Ximluci® registration

Xbrane Biopharma — Investor Day (September 2022) on 6ix